Ocular Patents (Class 424/427)
  • Patent number: 10973776
    Abstract: The present invention provides a sustained drug delivery system for the treatment of age-related macular degeneration (AMD), comprising corticosteroid encapsulated nanoparticles incorporated into a thermoreversible hydrogel. The corticosteroid may be triamcinolone acetate (TA), dexamethasone, or loteprednol etabonate (LE). The proposed drug delivery system is nontoxic to ARPE-19 (retinal pigment epithelium) cells and significantly reduces VEGF (vascular endothelial growth factor) expression as compared to solutions of the coticosteroids. The present invention provides sustained delivery of the corticosteroid to the posterior segment of the eye, reducing the frequency of intraocular injections necessary to maintain therapeutic concentrations.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: April 13, 2021
    Assignee: University of South Florida
    Inventors: Vijaykumar Bhadabhai Sutariya, Anjali A. Hirani, Yashwant V. Pathak
  • Patent number: 10953103
    Abstract: The present invention pertains to a composition comprising at least one biocompatible and biodegradable polymer, the polymer further comprising nanocarriers wherein the nanocarriers comprise a drug. Moreover, also encompassed by the invention is the use of the composition in the treatment of a disease and a method for manufacturing the composition.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: March 23, 2021
    Assignee: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V
    Inventors: Matthias Wacker, Susanne Beyer, Michael Parnham, Werner Mäntele, Li Xie, Vitali Vogel
  • Patent number: 10919853
    Abstract: Cross-linking agent(s), composition(s) made therefrom and use(s) thereof. For example, crosslinking agent(s) that are used to make composition(s) such as hydrogel material(s). Such materials are useful in the manufacture of biocompatible medical devices, for example, hydrogel materials having desirable physical properties for use as contact lense(s) and/or stimulating device(s).
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: February 16, 2021
    Assignee: GL CHEMTEC VISION INC.
    Inventors: Musa Alhakimi, Gamil Alhakimi, Lisa Studnicki
  • Patent number: 10881786
    Abstract: A wearable liquid supplying device for insulin injection is fixed on a user's body through a ring belt and includes a carrier body, a flow-guiding-and-actuating unit, a sensor, an air bag, a miniature air pump and a driving chip. The sensor measures sweat on human skin to detect a level of the blood glucose. The driving chip receives the glucose monitoring data and accordingly controls the actuation of the flow-guiding-and-actuating unit and the open/closed states of the switching valves. The miniature air pump is enabled to inhale gas into the air bag, so that the air bag is inflated and the ring belt contacts the human skin tightly. The flow-guiding-and-actuating unit is enabled to generate a pressure difference so that the insulin liquid is transported to a liquid guiding outlet through a liquid guiding channel and flows into the microneedle patch for being injected into the subcutaneous tissue.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: January 5, 2021
    Assignee: MICROJET TECHNOLOGY CO., LTD.
    Inventors: Hao-Jan Mou, Li-Pang Mo, Wei-Ming Lee, Chi-Feng Huang, Yung-Lung Han
  • Patent number: 10881787
    Abstract: A wearable liquid supplying device for human insulin injection is fixed on a body of human through a ring belt and includes a substrate, a flow-guiding-and-actuating unit, a sensor and a driving chip. The substrate has a liquid storage chamber. The flow-guiding-and-actuating unit has a liquid guiding channel in communication with a liquid storage outlet of the liquid storage chamber and a liquid guiding outlet. The sensor measures a blood glucose level and generates measured data correspondingly. The driving chip receives the measured data from the sensor and controls the actuation of the flow-guiding-and-actuating unit and the open/closed states of the switching valves. The flow-guiding-and-actuating unit is enabled to generate a pressure difference so that the insulin liquid is transported to the liquid guiding outlet through the liquid guiding channel and flows into the microneedle patch for allowing the microneedles to inject the insulin liquid into the subcutaneous tissue.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: January 5, 2021
    Assignee: MICROJET TECHNOLOGY CO., LTD.
    Inventors: Hao-Jan Mou, Li-Pang Mo, Wei-Ming Lee, Chi-Feng Huang, Yung-Lung Han
  • Patent number: 10869833
    Abstract: Drug delivery devices comprising a non-bioabsorbable polymer structure configured to support a composition comprising an active agent. The devices include a plurality of portions fused together and a recess configured to support the composition. At least one of the portions includes an impermeable polymer and at least one other portion includes a rate-limiting water-permeable polymer. The rate-limiting water-permeable polymer allows for transportation of the active agent to an exterior of the device.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: December 22, 2020
    Inventors: Casey Kopczynski, Cheng-Wen Lin, Chris Sutay
  • Patent number: 10864158
    Abstract: Multilayer thin film devices that include a bioactive agent for elution to the surrounding tissue upon administration to a subject are provided. The multilayer thin film devices are useful as medical devices, such as ocular devices. Also provided are methods and kits for localized delivery of a bioactive agent to a tissue of a subject, and methods of preparing the subject devices. The multilayer thin film medical device includes a first layer, a bioactive agent and a second layer. The first and the second layers may be porous or non-porous. The devices have a furled structure, suitable for administration to a subject.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: December 15, 2020
    Assignee: The Regents of the University of California
    Inventors: Tejal A. Desai, Mark Rory Steedman, Robert Bhisitkul, Daniel A. Bernards, Kevin D. Lance
  • Patent number: 10857215
    Abstract: Methods of using botulinum toxin based pharmaceuticals are disclosed. The methods cause vasodilatation and decreased flow resistance of certain vascular beds for the purpose of increasing blood flow to a region in order to positively impact deterioration from a number of diseases.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: December 8, 2020
    Assignee: Revance Therapeutics, Inc.
    Inventors: Gary E. Borodic, Martin A Acquadro
  • Patent number: 10813789
    Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: October 27, 2020
    Assignee: Dose Medical Corporation
    Inventors: David S. Haffner, Kenneth M. Curry, Harold A. Heitzmann, David Applegate
  • Patent number: 10813788
    Abstract: A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device may comprise a penetrable barrier to inject therapeutic agent into the device when implanted in the patient.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: October 27, 2020
    Assignee: ForSight Vision4, Inc.
    Inventors: Eugene de Juan, Jr., Yair Alster, Kathleen Cogan Farinas, K. Angela MacFarlane, Cary J. Reich, Randolph E. Campbell
  • Patent number: 10792248
    Abstract: An aqueous suspension preparation that comprises a macrolide antibacterial agent as an active component. The aqueous suspension preparation is characterized by comprising nanoparticles of a macrolide antibacterial agent and a dispersion stabilizer; an aqueous suspension in which the average particle size of nanoparticles is 500 nm or less and the D90 particle size is 1,500 nm or less; a parenterally administered pharmaceutical composition that comprises this aqueous suspension preparation; an injection preparation; and eye drops or ear drops, more specifically, eye drops for the treatment or prevention of inflammatory diseases of the eye or ear drops for the treatment or prevention of inflammatory diseases of the ear.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: October 6, 2020
    Assignee: ACTIVUS PHARMA CO., LTD.
    Inventors: Takahiro Tada, Kazuhiro Kagami, Shiro Yokota, Kenta Kikuchi
  • Patent number: 10744313
    Abstract: A therapeutic delivery device that provides a controlled release of high doses of a therapeutic agent in a local area, sustains the high dose controlled release with a percutaneous port for refilling the device, and is versatile for use with multiple types of therapeutic agents and/or implant systems. A rate determining/controlled release membrane is used to decrease the molecular mobility of the therapeutic compounds thereby controlling the therapeutic release profile. The therapeutic delivery device includes a body defining an internal reservoir for receiving a therapeutic agent and including a first membrane for providing a controlled release of the therapeutic agent to the surgical site, a port in fluid communication with the reservoir, a sleeve configured to encapsulate the body, and a rigid housing configured to support the body and a portion of the sleeve, the rigid housing configured to release the body and the sleeve after the body and the sleeve are anchored position relative to the surgical site.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: August 18, 2020
    Assignee: University of Utah Research Foundation
    Inventors: Dustin Williams, Nicholas Ashton
  • Patent number: 10737022
    Abstract: A liquid supplying device for a human insulin injection includes a substrate, a liquid storage chamber, a flow-guiding-and-actuating unit, a sensor and a driving chip. The flow-guiding-and-actuating unit includes a liquid guiding channel having a liquid guiding outlet in fluid communication with a liquid storage outlet of the liquid storage chamber. The sensor contacts with the human skin to measure a blood glucose level contained in sweat. The driving chip is configured to control the actuation of the flow-guiding-and-actuating unit, control open/closed states of the switching valves and receive the measured data from the sensor for determination. By driving the flow-guiding-and-actuating unit, a pressure gradient is generated, and an insulin liquid stored in the liquid storage chamber is transported to the liquid guiding outlet through the liquid guiding channel, flowing into a microneedle patch, and injected into a subcutaneous tissue through a plurality of hollow microneedles.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: August 11, 2020
    Assignee: MICROJET TECHNOLOGY CO., LTD.
    Inventors: Hao-Jan Mou, Li-Pang Mo, Hsuan-Kai Chen, Chi-Feng Huang, Yung-Lung Han
  • Patent number: 10712474
    Abstract: Disclosed are high refractive index, hydrophobic, acrylic materials. These materials have both high refractive index and a high Abbe number. This combination means the materials have a low refractive index dispersion and thus are especially suitable for use as intraocular lens materials. The materials are also suitable for use in other implantable ophthalmic devices, such as keratoprostheses, corneal rings, corneal implants, and corneal inlays.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: July 14, 2020
    Assignee: Alcon Inc.
    Inventor: Douglas Schlueter
  • Patent number: 10702471
    Abstract: The present invention relates to a preservative-free, aqueous solution in the form of eye drops packed in a container that ensures stability of the product, ideal eye drop volume and reduced drop volume variability and provides efficient dispensing.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: July 7, 2020
    Assignee: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Vasiliki Samara, Ioanna Koutri, Anastasia Kalaskani, Andreas Kakouris, George Gotzamanis
  • Patent number: 10627649
    Abstract: A conformable covering comprises an outer portion with rigidity to resist movement on the cornea and an inner portion to contact the cornea and provide an environment for epithelial regeneration. The inner portion of the covering can be configured in many ways so as to conform at least partially to an ablated stromal surface so as to correct vision. The conformable inner portion may have at least some rigidity so as to smooth the epithelium such that the epithelium regenerates rapidly and is guided with the covering so as to form a smooth layer for vision. The inner portion may comprise an amount of rigidity within a range from about 1×10?4 Pa*m3 to about 5×10?4 Pa*m3 so as to deflect and conform at least partially to the ablated cornea and smooth an inner portion of the ablation with an amount of pressure when deflected.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: April 21, 2020
    Assignee: JOURNEY1, INC.
    Inventors: Eugene de Juan, Jr., Cary J. Reich, Yair Alster, K. Angela Macfarlane, Doug Rimer, Douglas Sutton, Dean Carson, Enrique Barragan, Matt Clarke, Ashley Tuan, Brian Levy
  • Patent number: 10610349
    Abstract: The invention relates to devices and methods for deploying an implant. Preferably the device (10) deploys a flexible implant in an eye. In one embodiment, the device comprises a distal end and a proximal end, wherein the distal end is constructed and arranged to cause said implant to be flexed into a curved configuration when in a carried position and the device is configured to urge said flexed implant from said carried position to a deployed position. Embodiments with removable tips (13) and wheel actuators (14) are also disclosed.
    Type: Grant
    Filed: July 5, 2011
    Date of Patent: April 7, 2020
    Assignee: UCL BUSINESS LTD
    Inventors: Peter Coffey, Lyndon Da Cruz, Karen Cheetham
  • Patent number: 10603476
    Abstract: A microneedle including a projection having a through hole formed in the projection in a direction that the projection extends, and a tubular member having an end surface configured to support the projection when the end surface is pressed against a skin and a fluid is supplied through the through hole of the projection to the skin. The projection has a length H along the direction that the projection extends and the supporting surface has an area S such that a ratio of S/H is in a range of from 2.1 to 10.5.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: March 31, 2020
    Assignee: TOPPAN PRINTING CO., LTD.
    Inventor: Yoshihiro Kodama
  • Patent number: 10595876
    Abstract: A surgical tool for inserting a spile or plug into the punctal opening of a meatus such as a lacrimo-nasal canaliculus. The tool includes a distal end having a plug-carrying structure which includes distally extending rod for engaging an axial bore in the plug, and an abutment having a radial prominence supporting a penetration-resisting bearing surface which prevents over-insertion of the plug by contacting tissue surrounding the punctal opening. The abutment can be shaped and dimensioned to provide effective and comfortable penetration resistance while affording ample visibility to the surgeon user. The rod can be axially withdrawn through a rod tracking tube having a precisely dimensioned central lumen restricting off-axis movement of the rod. The abutment can be fixed to the rod or detached from it.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: March 24, 2020
    Inventor: Bruce B. Becker
  • Patent number: 10585213
    Abstract: The present invention provides an optical element which prevents a contaminant component adhering to the edge thereof from spreading through the capillary action and thus from forming a stain; and a display device including the element. The present invention directs to an optical element including: a base material including a front surface provided with projected portions at a pitch equal to or shorter than the wavelength of visible light, and a side surface surrounding the front surface; and a covering material covering at least one of an edge of the front surface and the side surface, the covering material filling gaps between the projected portions. The present invention also directs to a display device including such an optical element.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: March 10, 2020
    Assignee: SHARP KABUSHIKI KAISHA
    Inventor: Kenichiro Nakamatsu
  • Patent number: 10568987
    Abstract: A composite collagen hydrogel material for use in tissue engineering, and an implantable ophthalmic device comprising such composite material. The composite material comprises: a first collagen network comprising collagen crosslinked with a first crosslinking agent, and/or a second collagen network comprising collagen crosslinked with a second crosslinking agent, and a three dimensional collagen mesh comprising partially and plastically compressed collagen hydrogel with a compression degree of 50-95%, wherein the three dimensional collagen mesh is embedded in the first collagen network and/or second collagen network, and the first collagen network and/or the second collagen network and the three dimensional collagen mesh are physically and chemically interconnected in the composite collagen hydrogel material.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: February 25, 2020
    Assignee: LinkoCare Life Sciences AB
    Inventor: Mehrdad Rafat
  • Patent number: 10561734
    Abstract: Polymer and drug containing compositions and method of preparing such compositions are disclosed. The dispersed phase formulation has a polymer, a pharmaceutically or biologically active agent and a small fraction of low pKa acid additive. Stable, filter sterilizable, non-gelling solutions containing GnRH analogues at least at levels typically used in sustained release formulations and a method of increasing solubility of a high level of a GnRH analogue or a freeze-dried antgonist of GnRH in a polymer containing solution are also disclosed. The amount of the acid additive in the polymer solution is such that it is sufficient to increase the solubility of the high level of the GnRH analogue in the polymer solution without affecting the release characteristics of the microspheres prepared therefrom.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: February 18, 2020
    Assignee: OAKWOOD LABORATORIES
    Inventors: Bagavathikanun C. Thanoo, James Murtagh, Gonto Johns
  • Patent number: 10545341
    Abstract: Configurations are disclosed for a health system to be used in various healthcare applications, e.g., for patient diagnostics, monitoring, and/or therapy. The health system may comprise a light generation module to transmit light or an image to a user, one or more sensors to detect a physiological parameter of the user's body, including their eyes, and processing circuitry to analyze an input received in response to the presented images to determine one or more health conditions or defects.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: January 28, 2020
    Assignee: Magic Leap, Inc.
    Inventors: Nicole Elizabeth Samec, John Graham Macnamara, Christopher M. Harrises, Brian T. Schowengerdt, Rony Abovitz, Mark Baerenrodt
  • Patent number: 10532201
    Abstract: A drug administration device includes a substrate having a first surface, a projection extending from the first surface, and a solid drug. One direction that intersects with the first surface is a first direction, and one direction that extends along the first surface is a second direction. A groove serving as a receiving section is formed in the projection. The groove defines a cavity recessed in the first direction toward the substrate and extends in the second direction to open to a section of the peripheral surface of the projection. The drug is received in the groove.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: January 14, 2020
    Assignees: TOPPAN PRINTING CO., LTD., JAPAN AS REPRESENTED BY DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES
    Inventors: Hiroyuki Kato, Tomoya Sumida, Yoshihiro Kodama, Seishiro Naito
  • Patent number: 10518073
    Abstract: A delivery system, including: a material for storing molecules and/or nanoparticles by substantially binding said molecules and/or nanoparticles to said material; a means for applying an electric field to said material to release said molecules and/or nanoparticles; and a means for applying an ultrasonic signal to said material to transport said molecules and/or nanoparticles through said material to a surface for delivery to an entity.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: December 31, 2019
    Assignee: PolyPharma Pty Ltd
    Inventors: Harry Unger, Mark Unger, Donald Martin, David John Bull, Craig Andrews
  • Patent number: 10517759
    Abstract: The invention relates generally to medical devices and methods for reducing the intraocular pressure in an animal eye and, more particularly, to stent type devices for permitting aqueous outflow from the eye's anterior chamber and associated methods thereof for the treatment of glaucoma. Some aspects provide a self-trephining glaucoma stent and methods thereof which advantageously allow for a “one-step” procedure in which the incision and placement of the stent are accomplished by a single device and operation. This desirably allows for a faster, safer, and less expensive surgical procedure.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: December 31, 2019
    Assignee: GLAUKOS CORPORATION
    Inventors: Douglas Daniel Crimaldi, Charles Raymond Kalina, Jr.
  • Patent number: 10500163
    Abstract: A sterile pharmaceutical dosage form which comprises an ester capped lactide polymer, glycolide polymer or a lactide-glycolide copolymer hypercompressed with an active pharmaceutical ingredient wherein said sterile pharmaceutical dosage form has been sterilized with an electron beam and a method of preparing said sterile pharmaceutical dosage form.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: December 10, 2019
    Assignee: SUSTAINED NANO SYSTEMS LLC
    Inventors: Barry M. Libin, Jeffrey M. Liebmann, Weiliam Chen
  • Patent number: 10500281
    Abstract: What is disclosed is a semi-solid controlled release pharmaceutical composition containing biocompatible and bioerodible semi-solid lipid matrix incorporating local anesthetics agents to form a semi-solid solution, a method of using the pharmaceutical composition to treat, and a method of making the pharmaceutical composition.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: December 10, 2019
    Assignee: Mira Pharma Corporation
    Inventors: Hui Rong Shen, Na Gan
  • Patent number: 10478531
    Abstract: This document provides methods and materials for treating a mammal (e.g., a human) having one or more stenotic blood vessels. For example, amnion coated balloons that can be used in balloon angioplasty are provided.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: November 19, 2019
    Inventor: Gary M. Petrucci
  • Patent number: 10478527
    Abstract: This invention relates to biodegradable implants comprising a hydrogel carrier matrix having dispersed therein a multitude of particles, wherein each of the multitude of particles and/or the hydrogel carrier matrix includes an active pharmaceutical ingredient (API) for the treatment of transected peripheral nerve injuries. Each of the multitude of particles and/or the hydrogel carrier matrix includes pristine polymer particles, preferably the pristine polymer particles may be polymethylmethacrylate polymers and derivatives thereof, preferably poly(methacrylic-co-methyl methacrylate) (PMMA). The spheroidal particles may each be formed from an outer shell including a chitosan (CHT) poly(methacrylic-co-methyl methacrylate) (PMMA) polyelectrolyte complex (CHT-PMMA-PEC) and an inner core including crosslinked chitosan having dispersed therein PMMA nanoparticles.
    Type: Grant
    Filed: September 5, 2016
    Date of Patent: November 19, 2019
    Assignee: University of the Witwatersrand, Johannesburg
    Inventors: Viness Pillay, Yahya Essop Choonara, Pradeep Kumar, Lisa Claire Du Toit, Poornima Ramburrun
  • Patent number: 10449086
    Abstract: A conjunctival cover including an annular generally curved shell having a conjunctival portion structured to conform to and overly at least part of the conjunctiva of an eye. The annular generally partially spherical shell defines a generally central opening. The central opening is sized to leave a cornea of the eye substantially or partially uncovered when the conjunctival cover is applied to the eye.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: October 22, 2019
    Inventor: Vance M. Thompson
  • Patent number: 10441747
    Abstract: Methods and kits for delivering pharmaceutical agents to an adventitia and other regions outside an external elastic lamina (EEL) surrounding a blood vessel utilize a catheter having a needle. The needle is positioned in up to 5 mm beyond the EEL and delivers an amount of a pharmaceutical agent sufficient to circumferentially permeate around the blood vessel and, in many cases, extend longitudinally and radially along the blood vessel. Confirmation that a delivery aperture of the needle lies beyond the EEL may be required before delivering the pharmaceutical agent. In one example, catheters are used to deliver dexamethasone and other anti-inflammatory agents to a peripheral vasculature and other vasculature to treat peripheral vascular disease and other conditions.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: October 15, 2019
    Assignee: Mercator MedSystems, Inc.
    Inventor: Kirk Patrick Seward
  • Patent number: 10420724
    Abstract: Drug delivery using bio-affecting drugs, particularly with shape changing drug delivery devices. Embodiments are included for depots for delivery of a therapeutic agent that change from an elongated state ex vivo to a coil in vivo where the agent is released.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: September 24, 2019
    Assignee: Incept, LLC
    Inventors: Peter Jarrett, Michael J. McGrath, Timothy S. Jarrett, Rami El-Hayek, Andrew C. Vanslette, Courtney A. Rosales, Charles D. Blizzard, Amarpreet S. Sawhney
  • Patent number: 10406028
    Abstract: A surgical tool for inserting a spile or plug into the punctal opening of a meatus such as a lacrimo-nasal canaliculus comprises an oblong, hollowed member shaped and dimensioned to be conveniently manipulated with one hand and having at one end a punctal opening and meatus-dilating shaft and, at the opposite end, a plug inserter. The dilating shaft has a cross-diameter substantially equal to the cross-diameter of the plug and is terminated by a conical spike. The inserter comprises a tip extending axially from the member and having, at its distal end, a cup whose internal geometry is commensurate with a cap at the proximal end of the plug. A penetration-resisting bearing surface is provided by the cup rim. A notch through the cup wall improves visualization of the plug during insertion. A steel wire running through the inserter has its distal end inserted into the cap of the plug.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: September 10, 2019
    Inventor: Bruce B. Becker
  • Patent number: 10408974
    Abstract: Disclosed are high refractive index, hydrophobic, acrylic materials. These materials have both high refractive index and a high Abbe number. This combination means the materials have a low refractive index dispersion and thus are especially suitable for use as intraocular lens materials. The materials are also suitable for use in other implantable ophthalmic devices, such as keratoprostheses, corneal rings, corneal implants, and corneal inlays.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: September 10, 2019
    Assignee: Novartis AG
    Inventor: Douglas Schlueter
  • Patent number: 10406102
    Abstract: A pharmaceutical dosage form which comprises a lactide, glycolide or lactide-glycolide polymer, a block polymer of polyglycolide, trimethylene carbonate, poly-caprolactone, and polyethylene oxide that is combined with a peptide or protein therapeutic agent in the form of microparticles which are compressed using a pressure of 50,000 to 350,000 psi.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: September 10, 2019
    Assignee: SUSTAINED NANO SYSTEMS LLC
    Inventors: Barry M. Libin, Jeffrey M. Liebmann, Weiliam Chen
  • Patent number: 10398755
    Abstract: Disclosed are pharmaceutical compositions comprising clusterin and polypeptides substantially the same as clusterin and treatment methods for inflammatory diseases and dry eye disease. The pharmaceutical compositions include an isolated clusterin or an isolated polypeptide substantially the same as clusterin. The clusterin is preferably secreted clusterin. The method of treating dry eye disease includes administering to a patient in need an effective amount of a pharmaceutical composition comprising an isolated clusterin or an isolated polypeptide substantially the same as clusterin. The method of treating a disease state characterized by inflammation includes administering to a patient having the disease state an amount of isolated clusterin or a protein substantially the same as clusterin effective to decrease the activity of a matrix metallproteinase selected from the group consisting of MMP-9, MMP-2 and MMP-7.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: September 3, 2019
    Assignee: University of Southern California
    Inventors: M. Elizabeth Fini, Shinwu Jeong
  • Patent number: 10398763
    Abstract: Methods are provided for treating astigmatism in an eye of a patient. An axis of greater curvature of the eye is determined. A stiffening process is applied to a cornea of the eye in a pattern defined from the axis of greater curvature of the eye.
    Type: Grant
    Filed: January 28, 2014
    Date of Patent: September 3, 2019
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventors: William J. Dupps, Ibrahim Seven
  • Patent number: 10350161
    Abstract: The present invention relates to a preservative-free, aqueous solution in the form of eye drops packed in a container that ensures stability of the product, ideal eye drop volume and reduced drop volume variability and provides efficient dispensing.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: July 16, 2019
    Assignee: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Vasiliki Samara, Ioanna Koutri, Anastasia Kalaskani, Andreas Kakouris, George Gotzamanis
  • Patent number: 10336896
    Abstract: A method of forming a hybrid physically and chemically cross-linked double-network hydrogel with highly recoverable and mechanical properties in a single-pot synthesis is provided. The method comprises the steps of combining the hydrogel precursor reactants into a single pot. The hydrogel precursor reactants include water; a polysaccharide; a methacrylate monomer; an ultraviolet initiator; and a chemical crosslinker. Next the hydrogel precursor reactants are heated to a temperature higher than the melting point of the polysaccharide and this temperature is retained until the polysaccharide is in a sol state. Then the single-pot is cooled to a temperature lower than the gelation point of the polysaccharide and this temperature is retained to form a first network. Thereafter, photo-initiated polymerization of the methacrylate monomer occurs via the ultraviolet initiator to form the second network.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: July 2, 2019
    Assignee: The University of Akron
    Inventors: Jie Zheng, Qiang Chen, Chao Zhao
  • Patent number: 10315019
    Abstract: Implantable drug delivery devices include a housing having a closed drug reservoir lumen bounded by a first wall structure and a hydrophilic second wall structure, and a drug contained in the drug reservoir lumen, wherein the first wall structure is impermeable to the drug and the second wall structure is permeable to the drug. Methods of providing controlled release of drug to a patient include deploying a drug delivery device in the patient releasing a drug from the drug reservoir lumen via diffusion through the second wall structure.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: June 11, 2019
    Assignee: TARIS BIOMEDICAL LLC
    Inventors: Heejin Lee, Karen Daniel, Matthew Sansone
  • Patent number: 10314924
    Abstract: Methods for treating a human subject who has X-linked Retinitis Pigmentosa (XLRP) or another clinically-defined ophthalmological condition due to a loss-of-function mutation in the gene encoding the retinitis pigmentosa GTPase regulator (RPGR) protein, the method comprising administering to the subject a nucleic acid comprising an adeno-associated viral vector comprising an abbreviated human RPGR cDNA.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: June 11, 2019
    Assignees: Massachusetts Eye & Ear Infirmary, UCL Business PLC, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Michael A. Sandberg, Basil Pawlyk, Alan Finlay Wright, Xinhua Shu, Tiansen Li, Robin Ali
  • Patent number: 10314780
    Abstract: The invention refers to a drippable ophthalmic gel, said gel having composition comprising bimatoprost in an amount of 0.003 to 0.03% by weight, polyacrylate in an amount of >0.2% by weight, povidone (PVP), dextrane, polyethylene glycols (PEG), carboxymethyl cellulose (CMC) or poly(vinyl alcohol) (PVA) in an amount of 0.2 to 10% by weight, an isotonizing agent in an amount to produce an osmolality of 200 to 400 mosml/kg, a salt for adjusting the viscosity in an amount of 0.05 to 0.4% by weight, a base in an amount to adjust the pH to 6 to 8 and excipients normally used in ophthalmic gels, having a viscosity in the range of 200 to 2000 mPa·s.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: June 11, 2019
    Assignee: MEDPROJECT PHARMA-ENTWICKLUNGS-UND VERTRIEBSGESELLSCHAFT MBH
    Inventors: Heinz Polzer, Pierre-Paul Elena, Jürgen Senge
  • Patent number: 10307292
    Abstract: Provided is a device for use in controlling the liquid outflow from the anterior chamber of the eye, methods of draining aqueous humor from the anterior chamber to the intra-orbital space using the device, methods for controlling the liquid outflow from the anterior chamber of the eye and further surgical methods for implanting the presently described device.
    Type: Grant
    Filed: July 18, 2012
    Date of Patent: June 4, 2019
    Assignee: MOR RESEARCH APPLICATIONS LTD
    Inventor: Gilad Litvin
  • Patent number: 10300114
    Abstract: The present invention relates to sustained release drug delivery systems, medical devices incorporating said systems, and methods of use and manufacture thereof. The inventive systems feature bioerodible drug delivery devices that include biocompatible solid and biocompatible fluid compositions to achieve desired sustained release drug delivery.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: May 28, 2019
    Assignee: EyePoint Pharmaceuticals US, Inc.
    Inventors: Hong Guo, Jianbing Chen, Dongling Su, Paul Ashton
  • Patent number: 10278920
    Abstract: A drug delivery implant and a method of using the same are disclosed herein. In one or more embodiments, the method includes forming a pocket in the cornea of the eye to gain access to tissue surrounding the pocket; applying a photosensitizer inside the pocket so the photosensitizer permeates at least a portion of the tissue surrounding the pocket and facilitates cross-linking of the tissue surrounding the pocket; irradiating the cornea to activate cross-linkers in the portion of the tissue surrounding the pocket, and thereby stiffen a wall of the pocket and kill cells in the portion of the tissue surrounding the pocket; and before or after the portion of the tissue surrounding the pocket has been stiffened and is devoid of cellular elements by the activation of the cross-linkers, inserting a corneal drug delivery implant into the pocket configured to release one or more medications into the eye.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: May 7, 2019
    Inventor: Gholam A. Peyman
  • Patent number: 10231926
    Abstract: Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: March 19, 2019
    Assignee: Allergan, Inc.
    Inventors: Jane-Guo Shiah, Chetan Pujara
  • Patent number: 10231830
    Abstract: A prosthetic heart valve provided herein can include a kidney capsule tissue leaflet. In some cases, a prosthetic heart valve can include a plurality of leaflets secured together and retained within the expandable tubular member. The kidney capsule tissue can be obtained from a farm animal, such as a cow, pig, horse, goat, or sheep. In some cases, the kidney capsule tissue can be tensioned (e.g., bi-axially tensioned) and/or chemically cross-linked.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: March 19, 2019
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: Lynne E. Swanson, Crystal Marie Anderson-Cunanan, Katherine Cora Fazackerley, Philip D. Crompton
  • Patent number: 10226419
    Abstract: Pharmacologically active implants, in particular subcutaneous implants, intrauterine devices, and intravaginal rings, are provided herein. Methods for forming an active ingredient-containing core are described. Methods for laminating an active ingredient-containing core to form a rate-controlling sheath are also described.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: March 12, 2019
    Assignee: PROMED PHARMA, LLC
    Inventors: James H. Arps, Matthew Petersen
  • Patent number: 10213405
    Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: February 26, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin